FDA approves Aurobindo’s generic Exelon

SILVER SPRING, Md. — Aurobindo Pharma announced Monday that it had received final approval from the Food and Drug Administration for its generic Exelon (rivastigmine tartrate) capsules. The drug is indicated to treat mild to moderate Alzheimer’s-related dementia, as well as mild to moderate dementia associated with Parkinson’s disease. 

 

The capsules will be available in 1.5-, 3-, 4.5-, and 6-mg dosage strengths. The drug had annual sales of about $26.2 million for the 12 months ended February 2016, according to IMS Health.